openPR Logo
Press release

US FDA Final Rule Categorizes the Safety and Effectiveness of 28 Consumer Hand Sanitizer Active Ingredients

05-10-2019 01:33 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: SGS

/ PR Agency: Sugarloaf Marketing
The US Food and Drug Administration (FDA) has published a final rule on the safety and effectiveness of 28 active ingredients used in consumer hand sanitizers.

These 28 active ingredients are considered Category II – not generally recognized as safe and effective or misbranded. They include:
1. Benzethonium chloride
2. Chloroxylenol
3. Chlorhexidine gluconate
4. Cloflucarban
5. Fluorosalan
6. Hexachlorophene
7. Hexylresorcinol
8. Iodine complex (ammonium ether sulfate and polyoxyethylene sorbitan monolaurate)
9. Iodine complex (phosphate ester of alkylaryloxy polyethylene glycol)
10. Methylbenzethonium chloride
11. Nonylphenoxypoly (ethyleneoxy) ethanoliodine
12. Phenol (equal to or less than 1.5 percent or greater than 1.5 percent)
13. Poloxamer iodine complex
14. Povidone-iodine 5 to 10 percent
15. Secondary amyltricresols
16. Sodium oxychlorosene
17. Tribromsalan
18. Triclocarban
19. Triclosan
20. Triple dye
21. Undecoylium chloride iodine complex
22. Polyhexamethylene biguanide
23. Benzalkonium cetyl phosphate
24. Cetylpyridinium chloride
25. Salicylic acid
26. Sodium hypochlorite
27. Tea tree oil
28. Combination of potassium vegetable oil solution, phosphate sequestering agent, and triethanolamine

The FDA believes the nonmonograph status of these ingredients means they affect less than 3% of consumer antiseptic rubs, otherwise known as hand sanitizers, currently in the marketplace.

The FDA has also deferred making a final rule on the following three substances to allow the development and submission of new safety and effectiveness data. They are:
• Ethanol
• Isopropyl alcohol
• Benzalkonium chloride

In addition, the statistical analysis used for efficacy has been updated. It now requires bacterial log reduction studies to continue as a demonstration that an active ingredient is effective. The rules also require substances to participate in a randomized three-arm study containing:
1. Test
2. Active control
3. Negative control

The statistical analysis related to the log reduction criteria for classifying consumer antiseptic rub active ingredients is also to be considered Generally Recognized as Effective (GRAE).

The FDA has also updated the following requirements for testing efficacy:
• The test product should be non-inferior to an FDA-approved antiseptic rub as active control with a 0.5 margin (log10 scale)
• Requiring the test product should be superior to the negative control by a margin of 1.5 (log10 scale)
• A minimum sample size of 100 subjects per treatment arm
• Two adequate and well-controlled clinical simulation pivotal studies for the consumer antiseptic rub indication at two separate independent laboratory facilities by independent principal investigators must be conducted

Stakeholders are now advised to make sure their products comply with the latest regulations before offering hand sanitizers onto the market in the US.

SGS Cosmetics & Personal Care Testing Services
SGS provides testing, inspection, auditing and consulting services to manufacturers, distributors and importers to ensure a high level of product quality in every area. A global network of state-of-the-art laboratories offer custom-made solutions for chemical, biophysical, microbiological, stability and biological aspects. Learn more about SGS’s Cosmetics & Personal Care Testing Services. (www.sgs.com/en/consumer-goods-retail/cosmetics-personal-care-and-household/cosmetics-and-personal-care/testing)

SGS SafeGuardS keep you up to date with the latest news and developments in the consumer goods industry. Read the full US FDA Issues Final Rule on Safety and Effectiveness of Consumer Hand Sanitizers SafeGuardS. [www.sgs.com/en/news/2019/04/safeguards-05919-us-fda-issues-final-rule-on-safety-and-effectiveness-of-consumer-hand-sanitizers]

Subscribe here, www.sgs.com/subscribesg, to receive SGS SafeGuardS direct to your inbox.

For further information contact:

Joseph Scognamiglio
Technical Manager
Tel: +1 973-461-7937
Email: crs.media@sgs.com
Website: www.sgs.com/cosmetics

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 97,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.

1, Mons Calpe
Chitcombe Road
Broad Oak
Rye
East sussex
TN31 6EU

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US FDA Final Rule Categorizes the Safety and Effectiveness of 28 Consumer Hand Sanitizer Active Ingredients here

News-ID: 1734768 • Views:

More Releases from SGS

SGS Summarizes Strengthened EU Specifications for HBCDD Under the POP Recast Reg …
SGS, the world's leading testing, inspection and certification company, has published details of revised hexabromocyclododecane (HBCDD) specifications under the European Union's (EU) persistent organic pollutants legislation, the POP Recast Regulation (EU) 2019/1021. HBCDD is a flame retardant found in many consumer items, including upholstery and textiles, as well as in electric and electronic equipment. The EU Commission's Delegated Regulation (EU) 2024/2555 of March 21, 2024, published on September 27, 2024, revises the
SGS Summarizes Impact of EU Postponement of RED Cybersecurity Regulation Enforce …
SGS, the world's leading testing, inspection and certification company, has published SafeGuardS 095.23 to help stakeholders understand the impact of the decision to postpone the enforcement of the Radio Equipment Directive (RED) delegated act for cybersecurity until 2025. The European Commission (EC) originally planned to enforce the delegated act from August 2024. However, delays in the preparation of harmonized standards have meant the EC has now taken the decision to enforce
SGS Issues SafeGuardS for US CPSC Direct Final Rule for Bedside Sleepers
SGS, the world's leading testing, inspection and certification company, has published a SafeGuardS covering a recent direct final rule for bedside sleepers issued by the US Consumer Products Safety Commission (CPSC). Direct final rule 16 CFR 1222 was published on May 9, 2023, revising the safety standard for bedside sleepers. It incorporates the latest version of ASTM F2906-23 (Standard Consumer Safety Specification for Bedside Sleepers) with a modification. The modification involves
SGS Announces Complementary Webinar to Help Businesses Navigate Post-Brexit European Requirements for PPE
SGS Announces Complementary Webinar to Help Businesses Navigate Post-Brexit Euro …
SGS, the world's leading testing, inspection and certification company, has announced a webinar to help companies operating in European personal protective equipment (PPE) markets understand the implications of Brexit and the best route towards compliance. "Personal Protective Equipment: overview of EU and UK requirements" will be offered in two sessions on February 9, 2023, at 10.00 CET and 16.00 CET. It is aimed at operators throughout the PPE value chain, including

All 5 Releases


More Releases for FDA

DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes
FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding